Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione GPascale IRCCS, Naples, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Naples
Treatments:Chemotherapy, Biologic therapyHospital:Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione GPascale IRCCS
Drugs:Journal:Link
Date:Apr 2015

Description:

Patients:
This phase 2 study involved platinum-resistant or platinum-refractory ovarian cancer patients who had received prior chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 36 patients with a median age of 58 years, while group B had 37 patients with a median age of 56 years.

Treatment:
Patients in group A received chemotherapy with paclitaxel.

Patients in group B received chemotherapy with paclitaxel and biologic therapy with pazopanib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities in group A were of grade 3 and included anemia and fatigue. Grade 2 alopecia and nausea were also reported.

The most severe toxicities in group B were of grade 4 and included neutropenia and gastrointestinal perforation. Grade 3 high blood pressure and diarrhea were also reported.

Results:
The median overall survival in groups A and B was 13.7 and 19.1 months, respectively.

Support:
This study was partially supported by Glaxo Smith Kline (makers of pazopanib).

Correspondence: Dr. Sandro Pignata; email: [email protected]



Back